{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T16:50:03Z","timestamp":1761238203924,"version":"build-2065373602"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,11,1]],"date-time":"2015-11-01T00:00:00Z","timestamp":1446336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmacological and Toxicological Methods"],"published-print":{"date-parts":[[2015,11]]},"DOI":"10.1016\/j.vascn.2015.06.003","type":"journal-article","created":{"date-parts":[[2015,7,2]],"date-time":"2015-07-02T07:06:57Z","timestamp":1435820817000},"page":"1-6","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Cardiovascular safety risk assessment for new candidate drugs from functional and pathological data: Conference report"],"prefix":"10.1016","volume":"76","author":[{"given":"Stephanie K.","family":"Klein","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Will S.","family":"Redfern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vascn.2015.06.003_bb0005","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1177\/0192623311416259","article-title":"Induction of heart valve lesions by small-molecule ALK5 inhibitors","volume":"39","author":"Anderton","year":"2011","journal-title":"Toxicologic Pathology"},{"key":"10.1016\/j.vascn.2015.06.003_bb0015","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.yrtph.2012.09.007","article-title":"Integrated and translational nonclinical in vivo cardiovascular risk assessment: Gaps and opportunities","volume":"65","author":"Berridge","year":"2013","journal-title":"Regulatory Toxicology and Pharmacology"},{"key":"10.1016\/j.vascn.2015.06.003_bb0020","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1038\/nrd3845","article-title":"Reducing safety-related drug attrition: The use of in vitro pharmacological profiling","volume":"11","author":"Bowes","year":"2012","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.vascn.2015.06.003_bb0025","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1304382110","article-title":"Experimentally-calibrated population of models predicts and explains inter-subject variability in cardiac cellular electrophysiology","author":"Britton","year":"2013","journal-title":"PNAS"},{"issue":"4","key":"10.1016\/j.vascn.2015.06.003_bb0035","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1517\/14740338.2013.798300","article-title":"2012 Annual Meeting of the Safety Pharmacology Society: Spotlight on targeted oncology medicines","volume":"12","author":"Cavero","year":"2013","journal-title":"Expert Opinion on Drug Safety"},{"issue":"5","key":"10.1016\/j.vascn.2015.06.003_bb0040","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1097\/CJI.0000000000000036","article-title":"High-dose interleukin 2-induced myocarditis: Can myocardial damage reversibility be assessed by cardiac MRI?","volume":"37","author":"Chow","year":"2014","journal-title":"Journal of Immunotherapy"},{"issue":"5","key":"10.1016\/j.vascn.2015.06.003_bb0045","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1177\/0192623310374969","article-title":"Time course characterization of serum cardiac troponins, heart fatty acid-binding protein, and morphologic findings with isoproterenol-induced myocardial injury in the rat","volume":"38","author":"Clements","year":"2010","journal-title":"Toxicologic Pathology"},{"issue":"1","key":"10.1016\/j.vascn.2015.06.003_bb0050","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/toxsci\/kfu057","article-title":"An integrated characterization of serological, pathological, and functional events in doxorubicin-induced cardiotoxicity","volume":"140","author":"Cove-Smith","year":"2014","journal-title":"Toxicological Sciences"},{"issue":"6","key":"10.1016\/j.vascn.2015.06.003_bb0055","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s10565-011-9197-3","article-title":"NT-proBNP as a biomarker for the assessment of a potential cardiovascular drug-induced liability in beagle dogs","volume":"27","author":"Crivellente","year":"2011","journal-title":"Cell Biology and Toxicology"},{"key":"10.1016\/j.vascn.2015.06.003_bb0060","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1111\/bph.12979","article-title":"Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injury","volume":"172","author":"Cross","year":"2015","journal-title":"British Journal of Pharmacology"},{"issue":"6","key":"10.1016\/j.vascn.2015.06.003_bb0065","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1093\/eurheartj\/ehi092","article-title":"Anti-HERG activity and the risk of drug-induced arrhythmias and sudden death","volume":"26","author":"De Bruin","year":"2005","journal-title":"European Heart Journal"},{"key":"10.1016\/j.vascn.2015.06.003_bb0070","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1177\/0192623310378027","article-title":"Drug-induced valvulopathy: An update","volume":"38","author":"Elangbam","year":"2010","journal-title":"Toxicologic Pathology"},{"issue":"1","key":"10.1016\/j.vascn.2015.06.003_bb0075","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1248\/bpb.b12-00578","article-title":"MicroRNA 210 as a biomarker for congestive heart failure","volume":"36","author":"Endo","year":"2013","journal-title":"Biological & Pharmaceutical Bulletin"},{"key":"10.1016\/j.vascn.2015.06.003_bb0080","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/toxsci\/kfu198","article-title":"The concordance between nonclinical and phase I clinical cardiovascular assessment from a cross-company data sharing initiative","volume":"142","author":"Ewart","year":"2014","journal-title":"Toxicological Sciences"},{"issue":"4-6","key":"10.1016\/j.vascn.2015.06.003_bb0085","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/S0940-2993(98)80008-0","article-title":"Patterns of drug-induced cardiovascular pathology in the beagle dog: Relevance for humans","volume":"50","author":"Greaves","year":"1998","journal-title":"Experimental and Toxicologic Pathology"},{"key":"10.1016\/j.vascn.2015.06.003_bb0090","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/S0378-4274(99)00222-2","article-title":"Patterns of cardiovascular pathology induced by diverse cardioactive drugs","volume":"112\u2013113","author":"Greaves","year":"2000","journal-title":"Toxicology Letters"},{"key":"10.1016\/j.vascn.2015.06.003_bb0095","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.vascn.2010.05.010","article-title":"An approach to the assessment of drug-induced changes in non-electrophysiological properties of cardiovascular function","volume":"62","author":"Hamlin","year":"2010","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2015.06.003_bb0100","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.vascn.2012.01.001","article-title":"dP\/dt(max)\u2014A measure of \u2018baroinometry\u2019","volume":"66","author":"Hamlin","year":"2012","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"issue":"2","key":"10.1016\/j.vascn.2015.06.003_bb0110","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1093\/toxsci\/kft244","article-title":"Test of the usefulness of a paradigm to identify potential cardiovascular liabilities of four test articles with varying pharmacological properties in anesthetized guinea pigs","volume":"137","author":"Kijtawornrat","year":"2014","journal-title":"Toxicological Sciences"},{"issue":"4","key":"10.1016\/j.vascn.2015.06.003_bb0115","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1111\/j.1476-5381.2011.01255.x","article-title":"How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?","volume":"163","author":"Laverty","year":"2011","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.vascn.2015.06.003_bb0125","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1161\/ATVBAHA.115.305380","article-title":"Atherosclerosis","volume":"35","author":"Lu","year":"2015","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"issue":"3","key":"10.1016\/j.vascn.2015.06.003_bb0135","doi-asserted-by":"crossref","first-page":"e343","DOI":"10.1016\/j.ddtec.2012.04.004","article-title":"Technologies: Preclinical imaging for drug development","volume":"10","author":"Matthews","year":"2013","journal-title":"Drug Discovery Today Technologies"},{"issue":"2","key":"10.1016\/j.vascn.2015.06.003_bb0140","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.vascn.2010.05.018","article-title":"Evaluation of blood pressure measurement using a miniature blood pressure transmitter with jacketed external telemetry in cynomolgus monkeys","volume":"62","author":"McMahon","year":"2010","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2015.06.003_bb0145","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1177\/0192623314525686","article-title":"Nonclinical safety biomarkers of drug-induced vascular injury: Current status and blueprint for the future","volume":"42","author":"Mikaelian","year":"2014","journal-title":"Toxicologic Pathology"},{"key":"10.1016\/j.vascn.2015.06.003_bb0150","first-page":"491","article-title":"A cross company initiative assessing relationships between cardiovascular functional measurements and repeat-dose cardiovascular toxicity","volume":"126","author":"Milliken","year":"2012","journal-title":"Toxicologist"},{"key":"10.1016\/j.vascn.2015.06.003_bb0155","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.taap.2014.06.005","article-title":"Predicting changes in cardiac myocyte contractility during early drug discovery with in vitro assays","volume":"279","author":"Morton","year":"2014","journal-title":"Toxicology and Applied Pharmacology"},{"key":"10.1016\/j.vascn.2015.06.003_bb0160","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.vascn.2014.09.004","article-title":"Measurement of hyper- and hypotension during repeated dose toxicity studies in either freely moving or physically restrained cynomolgus monkeys","volume":"70","author":"Niehoff","year":"2014","journal-title":"Journal of Pharmacological and Toxicological Methods"},{"key":"10.1016\/j.vascn.2015.06.003_bb0165","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/188495b0","article-title":"Cardiac action and pacemaker potentials based on the Hodgkin\u2013Huxley equations","volume":"188","author":"Noble","year":"1960","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.vascn.2015.06.003_bb0170","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1177\/0192623310390392","article-title":"Continuing education course #1: Non-invasive imaging as a problem-solving tool and translational biomarker strategy in toxicologic pathology","volume":"39","author":"Peterson","year":"2011","journal-title":"Toxicologic Pathology"},{"key":"10.1016\/j.vascn.2015.06.003_bb0175","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ahj.2009.06.007","article-title":"Current challenges in the evaluation of cardiac safety during drug development: Translational medicine meets the Critical Path Initiative","volume":"158","author":"Piccini","year":"2009","journal-title":"American Heart Journal"},{"issue":"2","key":"10.1016\/j.vascn.2015.06.003_bb0180","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1093\/toxsci\/kfu312","article-title":"Assessment of cardiomyocyte contraction in human-induced pluripotent stem cell-derived cardiomyocytes","volume":"144","author":"Pointon","year":"2015","journal-title":"Toxicological Sciences"},{"key":"10.1016\/j.vascn.2015.06.003_bb0185","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/S0008-6363(02)00846-5","article-title":"Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: Evidence for a provisional safety margin in drug development","volume":"58","author":"Redfern","year":"2003","journal-title":"Cardiovascular Research"},{"issue":"S1","key":"10.1016\/j.vascn.2015.06.003_bb0190","first-page":"1081","article-title":"Impact and frequency of different toxicities throughout the pharmaceutical life cycle","volume":"114","author":"Redfern","year":"2010","journal-title":"The Toxicologist"},{"key":"10.1016\/j.vascn.2015.06.003_bb0195","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1039\/c3tx20093k","article-title":"Functional assessments in repeat-dose toxicity studies: The art of the possible","volume":"2","author":"Redfern","year":"2013","journal-title":"Toxicology Research"},{"issue":"11","key":"10.1016\/j.vascn.2015.06.003_bb0200","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.2174\/15680266113139990039","article-title":"Predictive in silico studies of human 5-hydroxytryptamine receptor subtype 2B (5-HT2B) and valvular heart disease","volume":"13","author":"Reid","year":"2013","journal-title":"Current Topics in Medicinal Chemistry"},{"issue":"2","key":"10.1016\/j.vascn.2015.06.003_bb0205","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1152\/ajplegacy.1970.218.2.437","article-title":"Construction of aortic flow pulse from pressure pulse","volume":"218","author":"Remington","year":"1970","journal-title":"American Journal of Physiology"},{"issue":"3","key":"10.1016\/j.vascn.2015.06.003_bb0210","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.ahj.2013.11.004","article-title":"Rechanneling the cardiac proarrhythmia safety paradigm: A meeting report from the Cardiac Safety Research Consortium","volume":"167","author":"Sager","year":"2014","journal-title":"American Heart Journal"},{"issue":"5","key":"10.1016\/j.vascn.2015.06.003_bb0215","doi-asserted-by":"crossref","first-page":"H1146","DOI":"10.1152\/ajpheart.00668.2011","article-title":"The Na+\/K+ pump is an important modulator of refractoriness and rotor dynamics in human atrial tissue","volume":"302","author":"Sanchez","year":"2012","journal-title":"American Journal of Physiology. Heart and Circulatory Physiology"},{"issue":"3","key":"10.1016\/j.vascn.2015.06.003_bb0220","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1177\/0192623312460924","article-title":"Current practices in preclinical drug development: Gaps in hemostasis testing to assess risk of thromboembolic injury","volume":"41","author":"Schultze","year":"2013","journal-title":"Toxicologic Pathology"},{"issue":"12","key":"10.1016\/j.vascn.2015.06.003_bb0225","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.2165\/00002018-200730120-00003","article-title":"Cardiac repolarisation and drug regulation: Assessing cardiac safety 10years after the CPMP guidance","volume":"30","author":"Shah","year":"2007","journal-title":"Drug Safety"},{"issue":"2","key":"10.1016\/j.vascn.2015.06.003_bb0230","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1124\/jpet.114.215202","article-title":"Prediction and modeling of effects on the QTc interval for clinical safety margin assessment, based on single-ascending-dose study data with AZD3839","volume":"350","author":"Sparve","year":"2014","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.vascn.2015.06.003_bb0235","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jtbi.2014.10.029","article-title":"Application of stochastic phenomenological modelling to cell-to-cell and beat-to-beat electrophysiological variability in cardiac tissue","volume":"365","author":"Walmsley","year":"2015","journal-title":"Journal of Theoretical Biology"},{"issue":"2","key":"10.1016\/j.vascn.2015.06.003_bb0240","doi-asserted-by":"crossref","first-page":"e56359","DOI":"10.1371\/journal.pone.0056359","article-title":"mRNA expression levels in failing human hearts predict cellular electrophysiological remodelling: A population-based simulation study","volume":"8","author":"Walmsley","year":"2013","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.vascn.2015.06.003_bb0250","first-page":"116","article-title":"Towards a drug concentration effect relationship for QT prolongation and torsades de pointes","volume":"5","author":"Webster","year":"2002","journal-title":"Current Opinion in Drug Discovery & Development"},{"key":"10.1016\/j.vascn.2015.06.003_bb0255","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1111\/j.1476-5381.2012.02200.x","article-title":"Computational assessment of drug-induced effects on the electrocardiogram: From ion channel to body surface potentials","volume":"168","author":"Zemzemi","year":"2013","journal-title":"British Journal of Pharmacology"}],"container-title":["Journal of Pharmacological and Toxicological Methods"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871915000726?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1056871915000726?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T23:59:21Z","timestamp":1761004761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1056871915000726"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,11]]},"references-count":45,"alternative-id":["S1056871915000726"],"URL":"https:\/\/doi.org\/10.1016\/j.vascn.2015.06.003","relation":{},"ISSN":["1056-8719"],"issn-type":[{"type":"print","value":"1056-8719"}],"subject":[],"published":{"date-parts":[[2015,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular safety risk assessment for new candidate drugs from functional and pathological data: Conference report","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmacological and Toxicological Methods","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vascn.2015.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}